ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,127.79
1.26%
US Tech 100
17,446.00
2.17%
다우존스 지수
38,675.68
1.18%
Bitcoin
63,892.52
1.60%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Vaxcyte Inc (PCVX)

  7. Vaxcyte Inc (PCVX) 뉴스

PCVX Vaxcyte Inc

65.96
1.41 (2.18%)
04 5월(5) 2024 - 마감
15분 지연
기업명 주식 심볼 시장 주식 타입
Vaxcyte Inc PCVX 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
Upgrade Icon
1.41 2.18% 65.96 09:00:00
개장가 저가 고가 종가 전일 종가
66.48 65.46 67.08 65.96 64.55
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
03/04/202405:05GLOBEVaxcyte to Present at the 23rd Annual Needham Virtual..
05/03/202411:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/03/202411:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/03/202411:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/03/202422:30GLOBEVaxcyte Completes Enrollment of Phase 2 Study Evaluating..
02/03/202406:02EDGAR2Form 144 - Report of proposed sale of securities
02/03/202406:00EDGAR2Form 144 - Report of proposed sale of securities
28/02/202406:58EDGAR2Form S-8 - Securities to be offered to employees in employee..
28/02/202406:02EDGAR2Form 8-K - Current report
28/02/202406:01GLOBEVaxcyte Reports Fourth Quarter and Full Year 2023 Financial..
21/02/202406:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/02/202406:05GLOBEVaxcyte to Report Fourth Quarter and Full Year 2023..
06/02/202407:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/02/202407:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/02/202408:39GLOBEVaxcyte Announces Closing of $862.5 Million Public Offering..
02/02/202406:07EDGAR2Form 144 - Report of proposed sale of securities
02/02/202406:06EDGAR2Form 144 - Report of proposed sale of securities
02/02/202406:05GLOBEVaxcyte to Present at the Guggenheim Healthcare Talks | 6th..
01/02/202407:26EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
01/02/202407:19EDGAR2Form 8-K - Current report
31/01/202413:37GLOBEVaxcyte Announces Pricing of $750 Million Public Offering
31/01/202406:13EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
31/01/202406:01GLOBEVaxcyte Announces Commencement of Proposed Public Offering..
29/01/202422:30GLOBEVaxcyte Completes Enrollment of Phase 1/2 Study Evaluating..
17/01/202406:01GLOBEVaxcyte Appoints Whitney Jones as Chief People Officer
05/01/202406:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/01/202406:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/01/202406:01GLOBEVaxcyte Provides Clinical and Regulatory Progress Update on..
03/01/202406:04EDGAR2Form 144 - Report of proposed sale of securities
03/01/202406:03EDGAR2Form 144 - Report of proposed sale of securities
12/12/202306:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202306:15EDGAR2Form 144 - Report of proposed sale of securities
06/12/202306:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/12/202308:35GLOBEVAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in..
02/12/202306:12EDGAR2Form 144 - Report of proposed sale of securities
30/11/202306:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/11/202306:46EDGAR2Form 3 - Initial statement of beneficial ownership of..
28/11/202322:32EDGAR2Form 8-K - Current report
28/11/202322:30GLOBEVaxcyte Appoints Jacks Lee to Board of Directors
28/11/202306:05EDGAR2Form 8-K - Current report
28/11/202306:00GLOBEVaxcyte Exercises Option and Enters into Manufacturing..
09/11/202322:30GLOBEVaxcyte Doses First Participants in Phase 1/2 Clinical Study..
07/11/202306:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202306:07EDGAR2Form 8-K - Current report
07/11/202306:03GLOBEVaxcyte Reports Third Quarter 2023 Financial Results and..
04/11/202305:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/11/202305:07EDGAR2Form 144 - Report of proposed sale of securities
01/11/202305:05GLOBEVaxcyte to Present at Upcoming Investor Conferences
19/10/202322:29DJNVaxcyte Gets FDA Go-Ahead on Pneumococcal Vaccine..
19/10/202321:30GLOBEVaxcyte Announces FDA Clearance of Investigational New Drug..

최근 히스토리

NASDAQ
PCVX
Vaxcyte
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유